Clinical Trials Logo

Depressive Disorder, Major clinical trials

View clinical trials related to Depressive Disorder, Major.

Filter by:

NCT ID: NCT03529513 Completed - Clinical trials for Major Depressive Episode

Medibio DDA Confirmatory Performance Study

Start date: August 18, 2017
Phase:
Study type: Observational

This study will determine whether the Medibio Depression Diagnostic Aid exceeds minimally acceptable thresholds for sensitivity and sensitivity in cases with a current depression episode and non-depressed controls.

NCT ID: NCT03523767 Recruiting - Clinical trials for Major Depressive Disorder

Effect of Systemic Inflammation on Emotion and Cognition in Patients With Mood Disorder - A Vaccine Study

Start date: February 7, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this pilot study is to investigate and compare the effect of a mild inflammatory stimulus (typhoid vaccine) on immune response, mood and cognition in healthy volunteers compared to patients with history Major Depressive Disorder (MDD) (not currently depressed and no symptoms of depression in the past 6 months).

NCT ID: NCT03514810 Completed - Clinical trials for Major Depressive Disorder

Combined Sertraline and Ketoprofen Administration in Major Depressive Disorder

Srt+ktpMDD
Start date: January 10, 2017
Phase: Phase 1
Study type: Interventional

Among the major depressive disorder (MDD) patients in the follow-up group, 16 were administered with 50 mg of oral sertralin once daily with placebo, whereas 28 were treated with 100 mg of ketoprofen once daily as adjuvant treatment for MDD. Controls do not take any medicine.

NCT ID: NCT03511599 Not yet recruiting - Clinical trials for Major Depressive Disorder

Cycloserine rTMS Plasticity Augmentation in Depression

Start date: June 15, 2018
Phase: Phase 1
Study type: Interventional

Transcranial magnetic stimulation (rTMS) is an investigational and therapeutic modality that impacts the connection strength between neurons by delivering patterned energy. In response to this patterned energy neurons fire and adapt by changing their connection strengths. This change in connection strengths is believed to be the underlying mechanism whereby this intervention has therapeutic benefit for this intervention in conditions such as depression. The purpose of this study is to test a means of enhancing the effect of rTMS using a medication (cycloserine) that has been shown to augment and stabilize activity dependent neuronal changes. The investigators wish to use the motor system, where the associated muscle response to brain stimulation can be measured, to probe activity dependent changes in connection strength between neurons.

NCT ID: NCT03505905 Not yet recruiting - Clinical trials for Major Depressive Disorder

A Neurosteroid Intervention for Menopausal and Perimenopausal Depression

Start date: April 2018
Phase: Phase 4
Study type: Interventional

HYPOTHESIS: Pregnenolone administration will be associated with greater reduction in depressive symptom severity than placebo in women with current mMDD. STUDY AIMS: Primary Aim: Determine if pregnenolone is associated with greater reduction in depressive symptom severity than placebo in women with mMDD, as measured by MADRS. Secondary Aims: 1. Determine if pregnenolone is associated with greater reduction in anxiety symptom severity than placebo in women with mMDD. 2. Determine if pregnenolone is associated with greater improvement in cognition than placebo in women with mMDD. 3. Determine if pregnenolone is associated with greater improvement in quality of life than placebo in women with mMDD. 4. Determine if pregnenolone is associated with greater improvement in vasomotor symptoms of menopause than placebo. Mechanistic Aims: 1. Determine whether changes in neurosteroid levels with pregnenolone mediate clinical response. 2. Determine if baseline neurosteroid levels predict pregnenolone response. 3. Determine whether depressive symptoms, anxiety, sleep or vasomotor symptoms improve first. A crossed-lagged panel model will explore serial correlations between changes in outcome measures.

NCT ID: NCT03492203 Recruiting - Major Depression Clinical Trials

Remote Cognitive Remediation for Depression

RECORD
Start date: December 2016
Phase: N/A
Study type: Interventional

Major depressive disorder is the number one cause of disability worldwide. Evidence regarding the effectiveness of various treatments for patients with severe depression is still lacking. Although many patients achieve treatment response, only a minority of patients achieve full remission and even fewer sustain it. In fact, within one month 10% will be re-hospitalized and the rate climbs to 30% within a year. Further, remission from depressive symptoms is a surprisingly poor predictor of recovery of community functioning following discharge. It is clear that the traditional focus on diagnostic symptoms is insufficient for promoting a full return to everyday functioning. The present aim is to examine the efficacy and effectiveness of treating neurocognition, a symptom that explains persistent deficits in community functioning for those with depression. The study design that maps on to the contemporary clinical setting, in order to reflect the changing landscape of inpatient and community treatment.

NCT ID: NCT03489122 Not yet recruiting - Clinical trials for Depressive Disorder, Major

A Randomized Control Trial Treating Depression With Yoga and Coherent Breathing Versus Walking in Veterans

Start date: October 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The proposed study addresses a gap regarding the need for effective Major Depressive Disorder (MDD) treatments and the 40% of individuals treated with antidepressant medications that do not achieve full remission. This study tests a novel approach for treating MDD in a Randomized Control Trial (RTC) using yoga versus walking interventions to correct an imbalance in the Autonomic Nervous System; an over active Sympathetic Nervous System (fight or flight) an underactive Parasympathetic Nervous System (PNS) (rest, renewal and social engagement) and associated under activity in the neurotransmitter, gamma aminobutyric acid (GABA). This novel approach is complimentary to the use of antidepressant medications that primarily target the monoamine systems. Low activity in the PNS and GABA systems are also found in MDD, PTSD, and Alcohol Use Disorder, disorders representing a high healthcare burden in the Veteran population. This intervention has potential to provide relief for MDD and other disorders relevant the Veteran population

NCT ID: NCT03487926 Not yet recruiting - Clinical trials for Inflammatory Bowel Diseases

Microglial Activation in Inflammatory Bowel Disease

Start date: May 1, 2018
Phase:
Study type: Observational

The purpose of this study is to monitor microglial activation in participants with inflammatory bowel disease (IBD) and investigate the relationship that exists between these patients and their risk of acquiring major depressive episodes (MDE). Patients with both IBD and MDE will be subsequently approached to participate in the study.

NCT ID: NCT03487198 Not yet recruiting - Clinical trials for Major Depressive Disorder

The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder

Start date: May 30, 2018
Phase: Phase 3
Study type: Interventional

This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of brexpiprazole as adjunctive therapy in the treatment of Major Depressive Disorder. A total of approximately 1100 subjects will be enrolled into the single-blind treatment for 6 weeks, and 480 incomplete responders will be randomized to brexpiprazole (2~3 mg) or placebo in a 1:1 ratio (approximately 240 subjects in each group), for treatment of 6 weeks.

NCT ID: NCT03484754 Recruiting - Major Depression Clinical Trials

Infiltrations of OnaBotulinum Toxin A in Resistant Depression: Comparison of Two Facial Injection Sites.

OnaDEP
Start date: April 1, 2018
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate in adult subjects with resistant depression the effect of an injection of botulinum toxin in the corrugator and procerus muscles, in comparison to the infiltration of the crow's feet area, in addition to the current antidepressant treatment.